
Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.
It also lists the most common “objectional conditions or practices” found during inspections.
In an effort to improve transparency,
The effort is part of the agency’s Transparency Initiative, which FDA Commissioner Margaret Hamburg, MD, launched in June 2009 in response to the Obama administration’s call for more transparency.
Nutritional Outlook thanks Harry Rice and Ullman, Shapiro & Ullman LLC for the tip.






